Is GeneDx Holdings (WGS) Attractive After Recent Share Price Weakness And DCF Upside?

• Wondering whether GeneDx Holdings at around US$69.84 is a bargain or already pricing in a lot of optimism? This article walks through what the numbers currently say about value.
• The stock has had a choppy run, with a 10.2% decline over the last 7 days, a 14.9% decline over the last 30 days, a 47.2% decline year to date, a very large 3 year return, and a 33.1% decline over the last year.
• These swings have kept GeneDx on the radar for investors watching for changing expectations and risk appetite. Recent coverage has focused on how the share price now sits well below recent highs, which has prompted fresh questions about whether the current level better reflects the business or overreacts to past concerns.
• Against that backdrop, GeneDx currently has a value score of 4/6. The rest of this article looks at how different valuation approaches line up, before finishing with a way to go beyond the usual ratios to understand what that score might really mean.

Find out why GeneDx Holdings's -33.1% return over the last year is lagging behind its peers.

Approach 1: GeneDx Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth today by projecting its future cash flows and discounting them back to a present value.

For GeneDx Holdings, the latest twelve month Free Cash Flow is about $15.0 million. Analysts have provided forecasts out to 2030, with Simply Wall St extrapolating further to build a 2 Stage Free Cash Flow to Equity model. Within this framework, projected Free Cash Flow reaches $325.6 million in 2030, with additional estimates running through 2035 based on the supplied growth assumptions.

When those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $379.21 per share. Compared with the recent share price of around $69.84, the DCF output implies the stock trades at an 81.6% discount to that estimate. This highlights a wide gap between the modelled value and the current market price.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests GeneDx Holdings is undervalued by 81.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for GeneDx Holdings.

Approach 2: GeneDx Holdings Price vs Sales

For companies that are not yet consistently profitable, the P/S ratio is often more useful than P/E because it anchors the valuation to revenue rather than earnings, which can be more volatile or negative during investment heavy periods.

Growth expectations and risk still matter here, because a higher growth, higher risk business might reasonably trade at a higher P/S than a mature, steadier one. What counts as a normal or fair multiple often reflects what investors are willing to pay for each dollar of sales given those trade offs.

GeneDx currently trades on a P/S of 4.78x, while the broader Healthcare industry sits around 1.19x and its peer group averages about 1.45x. Simply Wall St’s Fair Ratio for GeneDx is 4.78x. This is a proprietary estimate of what the P/S could be given factors such as its earnings profile, industry, profit margin, market cap and risk profile.

This Fair Ratio can be more tailored than a simple peer or industry comparison because it adjusts for those company specific inputs rather than assuming one size fits all. Here, the Fair Ratio is effectively in line with the current P/S, which points to the market pricing the stock roughly in line with that model.

Result: ABOUT RIGHT

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your GeneDx Holdings Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of GeneDx into a clear story that links the business set up to a forecast and then to a Fair Value, so you can see at a glance whether your story says the current price looks high or low, track how that changes as new news or earnings arrive, and compare very different perspectives such as a more cautious view anchored around a US$95.00 Fair Value versus a more optimistic view closer to US$156.97. All of this is available within an easy to use tool on the Community page that is already used by millions of investors.

Do you think there's more to the story for GeneDx Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com